Please note: The license is valid for 12 months from the date the report is sent.
Kinase inhibitors – a new study showing you trends, R&D and predicted revenues
Do you want to find sales potentials of kinase inhibitors? Now get the latest analysis for those cancer treatments. There you explore developments, other trends, results, opportunities and revenue forecasts.
Visiongain’s new report shows you what’s possible for drugs using protein kinase inhibition and related technology. There avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales. See now how you can gain.
You assess trends, technologies and products, benefiting your reputation for technological, medical and commercial insight.
Progress of that industry – see what’s possible for those anti-cancer medicines
There you explore the future of those therapies. Read on to investigate that industry and see how high its future sales could go.
Forecasts and other information showing technical, clinical and commercial possibilities
That new study gives you sales predictions to 2024 at overall world market, submarket, company, product and national level. See what the future holds. For those drugs you investigate where demand and money lie.
There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, that new analysis shows historical results, growth rates and market shares.
In that work you discover 77 tables, 81 charts and an interview with a company. There help your research, analyses and decisions, also benefiting your influence.
And the following sections explain what our new investigation gives you.
Forecasting of that world market and its segments
What’s the potential of that biomedical industry? What’re the secrets of its progress? Find in our report overall world revenue to 2024 from inhibition of protein kinases.There also find individual revenue predictions to 2024 – with discussions – for seven submarkets at world level:
- Bcr-Abl inhibitors
- Angiogenesis inhibitors
- EGFR inhibitors
- mTOR inhibitors
- Other kinase agents
- BRAF and MEK products
- Generic drugs (generics) and related medicines.
You assess outlooks for expansion in trade, hearing where potential sales increases exist. That work investigates products, uses and revenues past and future. Find what’s possible.
Our study also explores competition. There you see what’s happening for developers, producers and sellers of kinase inhibiting agents, understanding challenges, trends and outlooks. You also explore revenues by product.Drug forecasts – existing and expected therapies
Discover sales potentials for leading brands, too, seeing how they can compete and succeed. How will 35 cancer treatments perform to 2024 at world level?
Our work shows you individual revenue predictions for 24 top products, including Gleevec, Sprycel, Tasigna, Tarceva and Iressa. It also gives sales predictions for 11 expected drugs, including Palbociclib, Bemaciclib, Alectinib, Ceritinib and Idelalisib.
Also that work splits its overall world market into geographical forecasts.Healthcare in national markets – what outlooks for that business?
Advances in pharmaceutical biotechnology and healthcare expand use of anti-cancer drugs, including kinase inhibitors. See prospects for developed and developing regions.Our analyses show you individual revenue forecasts to 2024 for 11 countries:
- United States (US)
- Germany, France, UK, Italy and Spain (EU5), also with overall EU prediction
- Brazil, Russia, India and China (BRIC nations).
There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.
Also how do events, challenges and advances in technology affect that industry and market? O
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources